Format

Send to

Choose Destination
Nat Immunol. 2018 Nov;19(11):1179-1188. doi: 10.1038/s41590-018-0235-7. Epub 2018 Oct 17.

Recent progress in broadly neutralizing antibodies to HIV.

Sok D1,2,3,4, Burton DR5,6,7,8.

Author information

1
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA. dsok@iavi.org.
2
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA. dsok@iavi.org.
3
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA, USA. dsok@iavi.org.
4
International AIDS Vaccine Initiative, New York, NY, USA. dsok@iavi.org.
5
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA. burton@scripps.edu.
6
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA. burton@scripps.edu.
7
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA, USA. burton@scripps.edu.
8
Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA. burton@scripps.edu.

Abstract

In this Review, we highlight some recent developments in the discovery and application of broadly neutralizing antibodies (bnAbs) to human immunodeficiency virus (HIV); i.e., antibodies able to neutralize diverse isolates of HIV. We consider the characterization of novel bnAbs, recent data on the effects of bnAbs in vivo in humans and animal models, and the importance of both kinds of data for the application of Abs to prophylaxis and therapy and to guide vaccine design. We seek to place newly discovered bnAbs in the context of existing bnAbs, and we explore the various characteristics of the antibodies that are most desirable for different applications.

PMID:
30333615
PMCID:
PMC6440471
DOI:
10.1038/s41590-018-0235-7
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center